Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Upgrades Rigel Pharmaceuticals to Buy

Citigroup analyst Yigal Nochomovitz upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Neutral to Buy.
byBenzinga Newsdesk
December 2, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Citigroup analyst Yigal Nochomovitz upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Neutral to Buy.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cyprium Therapeutics, A Fortress Biotech Subsidiary Company, Completes Asset Transfer Of CUTX-101 Copper Histidinate Product Candidate For Treatment Of Menkes Disease, To Sentynl Therapeutics, A Wholly-Owned Subsidiary Of Zydus Lifesciences Ltd.

By Benzinga Newsdesk
December 6, 9:41 AM
Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium will retain 100% ownership over any FDA

FBIO